Developing selective small-molecule modulators of

Background
The National Institutes of Health (NIH) is the nation's leading medical research agency, focused on seeking fundamental knowledge about living systems to enhance health and reduce illness.

The NIH's National Center for Advancing Translational Sciences (NCATS) aims to catalyze innovative methods for developing diagnostics and therapeutics across various diseases. This contract seeks to develop selective small-molecule modulators of PIP4Kgamma, a lipid kinase involved in cellular processes relevant to neurological and metabolic disorders, to evaluate its therapeutic potential.

Work Details
The Contractor shall conduct a pharmacokinetic (PK) study of the compound NCGC00592266 in mice, administering it intraperitoneally at 10 mg/kg once daily for 7 consecutive days.

The study will involve collecting plasma, brain, liver, and pancreas samples at specified time points (5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 8 h, 12 h, and 24 h) with three mice per time point. Drug concentration analysis will be performed on these samples to evaluate systemic exposure and tissue distribution. The Contractor is responsible for providing analytical results and PK data in an Excel report. Deliverables include blood work results and PK results on day 1 and day 14 of the study, which will be sent via email to designated NCATS personnel.

Period of Performance
From September 4, 2026 to November 3, 2026.

Place of Performance
Bethesda, MD.

Bidder Requirements
The Contractor must provide qualified personnel including at least one PhD level Manager and one PhD level scientist for the estimated level of effort of one week.